Open AccessRevisiting EXTREME in the Immuno‐Oncology Era: How to Improve Its Outcomes
Author(s) -
Szturz Petr,
Vermorken Jan B.
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13966
Subject(s) - medicine , radiation therapy , head and neck squamous cell carcinoma , oncology , radiation oncology , head and neck , salvage therapy , intensive care medicine , head and neck cancer , surgery , chemotherapy
The choice of first‐line palliative treatment has always been one of the crucial decisions in the management of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck not suitable for salvage surgery or full‐dose radiotherapy. This commentary highlights trial results that show the importance of treatment sequencing decisions that should be of interest for daily practice.